Evaxion Biotech A/S Total Revenue

The latest total revenue for EVAX is $7.5M as of June 2026. That compares with $3.2M in the prior-year period — up 135.9% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Evaxion Biotech A/S's historical trend and sector peers before judging valuation or financial health.

Over the past year, EVAX's total revenue moved from $3.2M to $7.5M — a 135.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Evaxion Biotech A/S's operating scale or balance-sheet position.

Against Healthcare companies, EVAX currently prints $7.5M for total revenue, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Evaxion Biotech A/S's growth, margins, and balance sheet.

A total revenue figure of $7.5M for EVAX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting EVAX's total revenue ($7.5M), review year-over-year change from $3.2M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.